CV Sciences Q3: Revenue Stable Amid New Launches, Financing
CV Sciences Q3: Revenue Stable Amid New Launches, Financing
CEO CV Sciences, Inc. (OTCQB:CVSI), a hemp-focused wellness company, announced stable revenue in its Q3 2024 financials on Thursday. The company generated $3.9 million in revenue, a slight decline from $4.1 million in Q3 2023, yet maintained a gross margin of 46%, up from 45.1% the previous year.
大麻健康公司CV Sciences, Inc. (OTCQB: CVSI)宣佈週四在其2024年第三季度財務報表中營收穩定。該公司創造了390萬美元的營業收入，略低於2023年第三季度的410萬美元，但保持毛利率爲46%，高於去年的45.1%。
Q3 2024 Financial Highlights
2024年Q3財務亮點：
- Revenue: $3.9 million, a 5% decline from $4.1 million in Q3 2023 and stable compared to $4 million in Q2 2024.
- Net loss: $456,000, slightly higher than the $447,000 loss in Q3 2023.
- Adjusted EBITDA: Loss of $75,000, significantly improved from a loss of $361,000 in Q3 2023.
- Gross profit: $1.78 million, a slight decrease from $1.84 million in Q3 2023, reflecting an improved gross margin of 46%, up from 45.1% in the same period last year.
- 營業收入：390萬美元，比2013年第三季度的410萬美元下降了5%，與2024年第二季度的400萬美元持平。
- 淨虧損：45.6萬美元，略高於2013年第三季度的44.7萬美元虧損。
- 調整後的EBITDA：75,000美元的虧損，較2013年第三季度的36.1萬美元大幅改善。
- 毛利潤：178萬美元，略低於2013年第三季度的184萬美元，反映了46%的改善毛利率，高於去年同期的45.1%。
New Product Lines Boost Growth
新產品線推動增長
Operating with a cash balance of $1 million, CV Sciences recorded an adjusted EBITDA loss of $75,000, inching closer to cash flow break-even.
CV Sciences在手頭持有100萬美元的現金，記錄了調整後的EBITDA虧損75,000美元，逐漸接近現金流盈虧平衡。
Furthermore, the company's recent launches, including the cannabinoid-free +PlusHLTH supplement line, target cognitive health, stress relief and metabolism support. Additionally, CV Sciences expanded its pet health segment with hip, joint and calming chews, aiming to capture a broader consumer base.
此外，該公司最近推出了不含大麻的+PlusHLTH補充產品系列，目標是認知健康、緩解壓力和代謝支持。此外，CV Sciences通過臀部、關節和鎮靜咀嚼片擴大了寵物健康領域，旨在吸引更廣泛的消費群體。
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 訂閱本新聞快訊，每天免費獲取Benzinga獨家分析和大麻股行業及市場的最新資訊。如果您對業務認真，不容錯過。在這裏訂閱我們的新聞簡報。
Management Commentary
管理層評論
CEO Joseph Dowling highlighted the steady core revenue in a challenging environment, noting new products and acquisitions as positioning factors for growth in 2025. "Our third quarter 2024 progress demonstrates our continuous commitment to innovation and cost-efficient execution as we move closer to profitability and positive cash flow," Dowling said in a press release.
首席執行官約瑟夫·道林強調了在複雜環境中穩定的核心營業收入，指出新產品和收購是2025年增長的定位因素。道林在新聞稿中表示：「我們2024年第三季度的進展顯示了我們對創新和成本效益執行的持續承諾，將使我們更接近盈利和正現金流。」
Read Also: CBD Pioneer Charlotte's Web Narrows Loss In Q3, Focuses On Long-Term Growth
閱讀更多：CBD先驅夏洛特網絡（Charlotte's Web）Q3虧損收窄，專注長期增長
"We look forward to organically grow our business and pursue additional M&A opportunities in the near future to improve our top-line revenue, profitability and shareholder value," he added.
「我們期待有機地發展我們的業務，並在不久的將來尋求更多的併購機會，以改善我們的營業收入、盈利能力和股東價值，」他補充道。
CV Sciences Holds Top Market Spot
CV Sciences佔據了頂級市場位置
In Q3, CV Sciences further solidified its market position, maintaining top-seller status in the natural products retail channel, according to SPINS data. The company also secured $0.9 million in financing from Streeterville, aimed at fueling operational and product expansion.
在第三季度，CV Sciences進一步鞏固了其市場地位，在自然產品零售渠道中保持了暢銷產品的地位，根據SPINS數據。該公司還從Streeterville獲得了90萬美元的融資，旨在推動運營和產品擴張。
CVSI Price Action
CVSI's shares were trading 7.73% lower at $0.04235 per share at the time of this writing around 12:35 PM ET Thursday.
CVSI 價格走勢
CVSI的股票在美東時間週四12:35下午交易，每股下跌了7.73%，交易價爲0.04235美元。
- CBD Pharma Co. MediPharm: 37% Increase In Q3 International Sales, 15% YoY Revenue Growth
- CBD製藥公司MediPharm：Q3國際銷售增長37%，年增收入增長15%
譯文內容由第三人軟體翻譯。
